Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects between the ages of 18 and 55 years~* No history of clinically-relevant atopic or dermatological disease~* Positive reaction to intradermal injection of histamine~Exclusion Criteria:~* Subjects with screening laboratory test results that deviate from the upper and/or lower limits of the reference or acceptable range. The exception is that all liver function tests must not exceed the upper limit of normal.~* Subjects with evidence of, or history of, hepatic disorder, including acute or chronic hepatitis B or hepatitis C~* Intolerance to intradermal histamine injection.~* Subjects with dark skin (Part B only).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Arm A1 (Type: EXPERIMENTAL): Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999
- Arm A2 (Type: PLACEBO_COMPARATOR): Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo
- Arm B1 (Type: EXPERIMENTAL): Part B of study to assess effects of PF-05180999 on histamine-induced wheal
- Arm B2 (Type: EXPERIMENTAL): Part B of study to assess effects of PF-05180999 on histamine-induced wheal
- Arm B3 (Type: EXPERIMENTAL): Positive control to ensure histamine-induced wheal assay integrity
- Arm B4 (Type: EXPERIMENTAL): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).